**Product Specification Sheet**

**Product Name:** MLN-8237 (Alisertib)

**Catalog Number:**
- C6561-2 (powder)
- C6561-2s (10mM in DMSO)

**Package Size:** 2 mg

**Technical information:**

- **Chemical Formula:** $C_{27}H_{20}ClFN_4O_4$
- **CAS #:** 1028486-01-2
- **Molecular Weight:** 518.92
- **Purity:** >98%
- **Formulation:** White solid
- **Solubility:** Soluble in DMSO up to 50 mM
- **Chemical Name:** 4-[(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino]-2-methoxybenzoic acid
- **Storage:**
  - Store solid powder at 4°C desiccated;
  - Store DMSO solution at -20°C.

**Handling:**
- For C6561-2 (powder), add 386 µL of DMSO to make 10 mM solution.
- For C6561-2s, before open the vial, centrifuge the vial at 500rpm x 1 min in a 50 mL conical tube to ensure full sample recovery.

**Biological Activity:**
MLN-8237 is a second-generation, selective Aurora A kinase (AAK) inhibitor with an IC50 of 1 nM. MLN8237 shows 200-fold more selective activity against Aurora-A than related kinase Aurora-B. Inhibition of AAK by MLN-8237 induces cytotoxicity and cell arrest. Several completed as well as actively on-going phase I/II clinical trials evaluate MLN-8237 in advanced solid tumor as well as advanced hematological malignancies.

**Reference:**

For Technical Support: technical@cellagentech.com

*For research use only, not for clinical or diagnostic use.*